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Several acute and chronic inflammatory diseases are driven by accumulation of acti-
vated leukocytes due to enhanced chemokine expression. In addition to specific G 
protein-coupled receptor-dependent signaling, chemokine–glycosaminoglycan (GAG) 
interactions are important for chemokine activity in  vivo. Therefore, the GAG–chemo-
kine interaction has been explored as target for inhibition of chemokine activity. It was 
demonstrated that CXCL9(74-103) binds with high affinity to GAGs, competed with 
active chemokines for GAG binding and thereby inhibited CXCL8- and monosodium 
urate (MSU) crystal-induced neutrophil migration to joints. To evaluate the affinity and 
specificity of the COOH-terminal part of CXCL9 toward different GAGs in detail, we 
chemically synthesized several COOH-terminal CXCL9 peptides including the shorter 
CXCL9(74-93). Compared to CXCL9(74-103), CXCL9(74-93) showed equally high affinity 
for heparin and heparan sulfate (HS), but lower affinity for binding to chondroitin sulfate 
(CS) and cellular GAGs. Correspondingly, both peptides competed with equal efficiency 
for CXCL8 binding to heparin and HS but not to cellular GAGs. In addition, differences 
in anti-inflammatory activity between both peptides were detected in  vivo. CXCL8-
induced neutrophil migration to the peritoneal cavity and to the knee joint were inhibited 
with similar potency by intravenous or intraperitoneal injection of CXCL9(74-103) or 
CXCL9(74-93), but not by CXCL9(86-103). In contrast, neutrophil extravasation in the 
MSU crystal-induced gout model, in which multiple chemoattractants are induced, 
was not affected by CXCL9(74-93). This could be explained by (1) the lower affinity of 
CXCL9(74-93) for CS, the most abundant GAG in joints, and (2) by reduced competition 
with GAG binding of CXCL1, the most abundant ELR+ CXC chemokine in this gout 
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model. Mechanistically we showed by intravital microscopy that fluorescent CXCL9 
(74-103) coats the vessel wall in vivo and that CXCL9(74-103) inhibits CXCL8-induced 
adhesion of neutrophils to the vessel wall in the murine cremaster muscle model. Thus, 
both affinity and specificity of chemokines and the peptides for different GAGs and the 
presence of specific GAGs in different tissues will determine whether competition can 
occur. In summary, both CXCL9 peptides inhibited neutrophil migration in vivo through 
interference with GAG interactions in several animal models. Shortening CXCL9(74-103) 
from the COOH-terminus limited its GAG-binding spectrum.
Keywords: chemokine, cXcl9, glycosaminoglycan, neutrophil, anti-inflammatory, gout, cremaster muscle
inhibitor of human immunodeficiency virus infection and as a 
stem cell mobilizer. Recently, intact modified chemokines were 
developed that interfere with the binding of chemokines to GAGs 
(33, 34). These modified chemokines have, in comparison with 
their natural human chemokine counterpart, an enhanced affinity 
for GAGs but a decreased affinity for their GPCRs. In this way, 
the modified chemokines or decoy chemokines can compete with 
functional chemokines for GAG binding. Thereby, they reduce 
chemokine immobilization and presentation and enhance the 
inhibition of chemokine-induced leukocyte migration. It has been 
shown that PA401, a CXCL8-based decoy protein, exerts strong anti-
inflammatory activity in vivo (35–38). Also CCL2- and CXCL12-
based decoy proteins with high GAG-binding affinity and reduced 
activity on GPCRs have been developed (39, 40). Interference with 
GAG interactions also forms the basis for the inhibition of lym-
phocyte migration with the spiegelmer NOX-A12 (41). This RNA 
oligonucleotide competes with GAGs for the binding to CXCL12, 
leading to neutralization of CXCL12 activity in vivo. More recently, 
COOH-terminal peptides of the chemokine CXCL9 or monokine 
induced by interferon-γ (MIG) were described as potent GAG-
binding peptides (42, 43). The CXCL9(74-103) peptide could 
inhibit the in vivo chemotactic activity of CXCL8 by competing 
with CXCL8 for the binding to GAGs. Also in a murine model of 
monosodium urate (MSU) crystal-induced gout, the peptide was 
able to inhibit neutrophil extravasation. Reducing the length of 
the CXCL9 peptide gradually decreased the capacity to compete 
with CXCL8 for GAG binding and CXCL9(86-103) was unable to 
inhibit chemotactic activity of CXCL8 in vivo. These data stress the 
importance of amino acids 74–78 and two typical heparin-binding 
motifs (BBXB and BBBXXB), present in CXCL9(74-103), for the 
GAG-binding characteristics.
In this study, we investigated in more detail the specificity of 
chemokine-derived GAG-binding peptides and we evaluated the 
potential of such peptides to interfere with in  vivo neutrophil 
adhesion and migration to different tissues (peritoneal cavity, 
joints, and muscles) in mice.
MaTerials anD MeThODs
cells
Chinese hamster ovary (CHO) cells were a gift from M. Parmentier 
(ULB, Brussels, Belgium) and were cultured in Ham’s F-12 
medium (with l-glutamine; Lonza, Belgium) supplemented 
inTrODUcTiOn
Several acute and chronic inflammatory diseases, such as gout 
and rheumatoid arthritis, are characterized by enhanced expres-
sion of chemokines and accumulation of activated leukocytes in 
tissues (1–6). Chemokines or chemotactic cytokines are proteins, 
consisting of 60–110 amino acids, which play an important role 
in the migration of leukocytes (7–10). Chemokines are classified 
into C, CC, CXC, and CX3C subfamilies, based on the arrange-
ment of conserved NH2-terminal cysteine motifs. For most 
chemokines an alternative biological classification can be made 
between homeostatic or constitutively expressed chemokines, 
and inflammatory or inducible chemokines. The latter subclass 
is locally secreted by tissue cells and resident leukocytes upon 
infection or tissue damage, thereby creating a gradient along 
which leukocytes can migrate from the blood vessel to the site 
of inflammation (11–14). To create such a leukocyte migration 
inducing gradient, it is necessary that chemokines are presented 
on the endothelium at the site of inflammation through binding 
to glycosaminoglycans (GAGs), thereby preventing chemokine 
diffusion and degradation and retaining high local chemokine 
concentrations. Subsequently, GAG-bound chemokines interact 
with their G protein-coupled receptors (GPCRs), expressed by 
specific circulating leukocyte subtypes. This results in adhesion 
to and extravasation of leukocytes through the endothelium 
(15–17). Once leukocytes enter the tissue, they can migrate to the 
site of inflammation through the gradient of local GAG-bound 
chemokines. The binding of chemokines to GAGs has been 
proven to be indispensable for chemokine activity in vivo (18–20). 
Chemokine variants with mutations in their GAG-binding motif 
showed inactive in vivo due to abrogated GAG binding, although 
receptor binding and chemotactic activity in  vitro are seldom 
affected (21, 22). In addition, leukocytes of mice with disturbed 
heparan sulfate (HS) synthesis in endothelial cells and leukocytes 
showed reduced chemokine-induced migration (23).
Because of their essential role for the migration of leukocytes, 
chemokines and their GPCRs can serve as potential targets for the 
development of new anti-inflammatory drugs (24–26). Several 
neutralizing ligands or antibodies, modified chemokines or small 
molecules have been developed as antagonists (27–30). However, 
only two chemokine receptor antagonists are currently used as ther-
apeutics, namely, Maraviroc (a CCR5 antagonist) and AMD3100 
(a CXCR4 antagonist) (31, 32). Remarkably, these antagonists 
are not used as anti-inflammatory drugs, but, respectively, as an 
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with 10% fetal calf serum (FCS) and 0.8% G418 (Geneticin®; 
Life Technologies), as described (44). To inhibit sulfation of cel-
lular GAGs, CHO cells were cultured in the presence of 100 mM 
sodium chlorate (NaClO3) for 24 h as previously described (42).
Mice
Animal experiments at the Rega Institute for Medical Research, 
University of Leuven, were carried out in female adult NMRI 
mice, purchased from Elevage Janvier (Le Genest Saint Isle, 
France), in agreement with the Ethical Committee for Animal 
Care and Use of the KU Leuven and in adherence to the interna-
tional guidelines for animal ethics and welfare. Mouse studies at 
the Federal University of Minas Gerais were performed in adult 
C57BL/6J mice. The experiments were approved by the Animal 
Ethical Committee of the Federal University of Minas Gerais. 
Mice were sacrificed by i.p. injection of an overdose of nembutal 
or ketamine (150 mg/kg) and xylazine (20 mg/kg) prior to the 
collection of joint lavages. For the intravital microscopy studies, 
male C57Bl/6J mice were purchased from Jackson Laboratories 
(Bar Harbor, ME, USA). Animals were maintained in a specific 
pathogen-free environment at the University of Calgary Animal 
Resource Centre. All experimental animal protocols were 
approved by the University of Calgary Animal Care Committee 
and were in compliance with the Canadian Council for Animal 
Care Guidelines.
solid-Phase synthesis of cOOh-Terminal 
Peptides
COOH-terminal peptides of CXCL4 [CXCL4(47-70)] and 
CXCL9 [CXCL9(74-103), CXCL9(74-93), CXCL9(86-103)] were 
chemically synthesized using fluorenyl methoxycarbonyl (Fmoc) 
chemistry using an Activo-P11 automated synthesizer (Activotec, 
Cambridge, UK), as previously described (45). Part of the material 
was site-specifically biotinylated or fluorescently labeled at the 
NH2-terminus using biotin-p-nitrophenyl ester (Novabiochem, 
Darmstadt, Germany) or 5(6)-carboxytetramethylrhodamine 
(TAMRA; Merck Millipore, Darmstadt, Germany), respectively 
(42). After synthesis, intact synthetic peptides were purified and 
identified by mass spectrometry (Amazon SL or Amazon Speed 
ETD ion trap, Bruker, Bremen, Germany).
isothermal Fluorescence Titration (iFT)
To study the interaction between CXCL9(74-93) and GAGs, titra-
tion experiments were performed as described by Gerlza et  al. 
(46) using TAMRA-labeled synthetic CXCL9(74-93), TAMRA-
labeled synthetic CXCL9(74-103), HS (Iduron BN1, Manchester, 
UK), low molecular weight heparin (LMWH; Iduron BN5), and 
chondroitin sulfate (CS; Carbosynth, Compton, UK).
Binding of cOOh-Terminal Peptides to 
cellular gags and competition with 
cXcl8
Binding of biotinylated CXCL9(74-103) and CXCL9(74-93) to 
CHO cells was assessed by flow cytometry as recently described 
(42). Briefly, cells were detached with phosphate-buffered saline 
(PBS) with 0.02% ethylenediaminetetraacetic acid (EDTA) 
and incubated with NH2-terminally biotinylated peptides. 
Subsequently, cells were incubated with streptavidin-allophyco-
cyanin (BD Biosciences, San Jose, CA, USA) and analyzed by flow 
cytometry (FACSCalibur, BD Biosciences). To confirm inhibition 
of sulfation of cellular GAGs, part of the cells were stained with 
a mouse monoclonal anti-human HS antibody (Immunosource, 
Schilde, Belgium) and a secondary phycoerythrin-labeled goat 
anti-mouse antibody (BD Biosciences). Finally, cells were ana-
lyzed by flow cytometry. Analogously, binding of 100 nM bioti-
nylated CXCL8 in the presence or absence of CXCL9(74-103) or 
CXCL9(74-93) was compared on CHO cells.
competition of cOOh-Terminal Peptides 
for Binding of chemokines to gags
The ability of the COOH-terminal peptides of CXCL9 and 
CXCL4 to compete for GAG binding with the inflammatory 
chemokines CXCL8 and CXCL1 was evaluated on heparin-
binding plates [BD Biosciences or produced by Jason Whittle 
(School of Engineering/Future Industries Institute, University 
of South Australia, Australia)] (42, 47). In brief, GAGs (heparin, 
HS, and CS; Iduron; 25 µg/ml) were coated overnight at room 
temperature. Dilutions of COOH-terminal CXCL9 or CXCL4 
peptide combined with recombinant human CXCL8(1-77) or 
recombinant murine CXCL1(1-72) (Peprotech, Rocky Hill, NJ, 
USA) were added in duplicate and incubated for 2  h at 37°C. 
Subsequently, bound CXCL8 or CXCL1 was detected with 
biotinylated polyclonal rabbit anti-human CXCL8 or biotinylated 
polyclonal goat anti-mouse CXCL1 (Peprotech) and horse radish 
peroxidase-labeled streptavidin. Finally, the peroxidase activity 
was quantified at 450 nm.
cXcl8-induced Migration of neutrophils 
In Vivo
In vivo neutrophil extravasation to the peritoneal or the knee 
cavity was examined, respectively, by intraperitoneal or intra-
articular injection, of endotoxin-free recombinant CXCL8(1-77) 
(PeproTech) or vehicle (PBS) in female NMRI or C57BL/6 mice, 
as described previously (42, 48). Simultaneously, synthetic CXCL9 
peptide was co-injected either intraperitoneally or injected intra-
venously. After 2 h (peritoneal cavity) or 3 h (knee cavity), mice 
were sacrificed. The peritoneal cavity was washed with saline 
enriched with 2% FCS and 20 U/ml heparin and total leukocyte 
counts were determined. For the preparation of cytospins, 105 
cells were used and absolute number and percentage of neutro-
phils in the lavages were determined in duplicate independently 
by two researchers by differential microscopic counting. The 
cells present in the tibiofemoral articulation were harvested by 
washing the cavity with 10 µl of 3% (w/v) bovine serum albumin 
in PBS and diluted in 90 µl of 3% (w/v) bovine serum albumin 
in PBS. The number of total leukocytes was determined by 
counting leukocytes in a Neubauer chamber after staining with 
Turk’s solution. Differential counts were obtained from cytospin 
preparations by evaluating the percentage of each leukocyte type 
on a slide stained with May-Grunwald-Giemsa solution.
Intravenously injected fluorescent CXCL9(74-103) was dete-
cted in plasma after different time intervals by spectrofluorometric 
TaBle 1 | Overview of the amino acid sequence of the cOOh-terminal 
peptides of cXcl9 and cXcl4 synthetized to investigate their 
glycosaminoglycan-binding affinity and their anti-inflammatory function.
Peptide amino acid sequence Mr (Da)
CXCL9(74-103) 74KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT103 3,661.4
CXCL9(74-93) 74KKKQKNGKKHQKKKVLKVRK93 2,460.1
CXCL9(86-103) 86KKVLKVRKSQRSRQKKTT103 2,199.7
CXCL4(47-70) 47NGRKICLDLQAPLYKKIIKKLLES70 2,785.4
Biotin-
CXCL9(74-93)
Biotin-74KKKQKNGKKHQKKKVLKVRK93 2,686.4
TAMRA-
CXCL9(74-93)
TAMRA-74KKKQKNGKKHQKKKVLKVRK93 2,871.5
Biotin-
CXCL9(74-103)
Biotin-
74KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT103
3,887.7
TAMRA-
CXCL9(74-103)
TAMRA-
74KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT103
4,072.8
The amino acid sequence and the Mr are listed. For clarity, basic amino acids were 
underlined.
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analysis and quantified against murine plasma spiked with known 
concentrations of the fluorescent peptide.
MsU crystal-induced gout in Mice
Monosodium urate crystals were prepared as described previously 
(42, 49) and were injected (100 µg in 10 µl) in the tibiofemoral 
knee joint of C57Bl/6 mice. A group of mice received CXCL9 
peptide or vehicle intravenously and the cells present in the 
tibiofemoral articulation were harvested 3  h after MSU crystal 
administration. The total and differential leukocyte counts were 
determined.
In Vivo neutrophil recruitment into the 
cremaster Muscle
Mice were anesthetized by intraperitoneal injection of 200 mg/kg 
ketamine (Bayer Inc. Animal Health) and 10  mg/kg xylazine 
(Bimeda-MTC). After anesthesia, the right jugular vein was can-
nulated for maintenance of anesthesia and to permit the delivery 
of the fluorescence-labeled antibodies. Mice were injected 
intravenously (via jugular vein) with either saline or CXCL9(74-
103) 5 min prior to an intrascrotal injection of 1 or 3 µg CXCL8. 
The animals were placed on a water-heated operating table to 
maintain body temperature at ~37°C. The depth of anesthesia 
was controlled by regularly monitoring peripheral reflexes. The 
cremaster muscle was prepared as previously described (50). 
Briefly, the muscle was dissected free from other tissues and 
opened longitudinally with cautery. The muscle was held flat on 
a cover slip by attaching five sutures in the corner of the tissue 
and the tissue was then constantly superperfused (1 ml/min) with 
pre-warmed bicarbonate buffered saline (pH 7.4), throughout the 
experiment. Neutrophils were stained by intravenous injected 
anti-Ly6G-A647 home labeled antibodies (anti-Ly6G, clone 
1A8, was purchased from BioLegend and coupled to Alexa647 
with the ThermoFisher protein labeling kit). In experiments in 
which unlabeled CXCL9(74-103) was used (evaluation of neu-
trophil adherence), neutrophils were labeled with PE-conjugated 
anti-Ly6G antibodies (eBiosciences) and endothelium with 
anti-CD31-A647 antibodies (BD Biosciences and coupled to 
Alexa647 with the ThermoFisher protein labeling kit). Single 
unbranched cremasteric venules with a diameter of ~25–40 μm 
were selected and their blood flow was recorded during a 5 min 
period. Spinning disk confocal intravital microscopy was per-
formed using an Olympus BX51W1 (Olympus, Center Valley, PA, 
USA) upright microscope equipped with a 20×/0.95 XLUM Plan 
Fl water immersion objective. The microscope was equipped with 
a confocal light path (WaveFx, Quorum, Guelph, ON, Canada) 
on a Yokogawa CSU-10 head (Yokogawa Electric Corporation, 
Tokyo, Japan). Sensitivity settings were maintained at the same 
level for all experiments. A 512 × 512 pixel back-thinned EMCCD 
camera (C9100-13, Hamamatsu, Bridgewater, NJ, USA) was 
used for fluorescence detection. Volocity Acquisition software 
(Improvision Inc., Lexington, MA, USA) was used to drive the 
confocal microscope. Images captured using the spinning disk 
were processed and analyzed in Volocity 4.20. Periods of 5 min/
field of view were recorded at 45, 60, and 90 min after CXCL8 
administration. A neutrophil was considered to be adherent 
if it remained stationary for at least 30  s, and total neutrophil 
adhesion was quantified as the number of adherent cells within a 
100-µm length of venule.
Alternatively, to evaluate the stability of the peptide on 
vascular endothelium, fluorescent CXCL9(74-103) was injected 
intravenously and visualized by intravital microscopy after dif-
ferent time intervals.
statistical analysis
All statistical analyses were performed using Statistica software 
version 13.1 (Dell, USA). The Mann–Whitney U-test was used to 
compare means or medians from independent groups (*p < 0.05; 
**p < 0.01; ***p < 0.005).
resUlTs
chemical synthesis and labeling  
of cXcl9(74-103) and cXcl9(74-93)
The highly cationic COOH-terminal peptides of CXCL9, namely, 
CXCL9(86-103), CXCL9(74-103), and CXCL9(74-93), were 
chemically synthesized, deprotected, and purified by RP-HPLC 
to evaluate their biological function (Table 1). Part of the peptides 
was site-specifically biotinylated or fluorescently labeled at the 
NH2-terminus. The Mr of the unlabeled and labeled purified 
synthetic peptides was confirmed by ion trap mass spectrom-
etry. Figure 1 shows the mass spectra of CXCL9(74-93), NH2-
terminally biotinylated CXCL9(74-93), and NH2-terminally 
TAMRA-labeled CXCL9(74-93). The experimentally determined 
Mr corresponded to the theoretical Mr of 2,460.1, 2,686.4, and 
2,871.5 for CXCL9(74-93), biotin-CXCL9(74-93), and TAMRA-
CXCL9(74-93), respectively. In addition, a COOH-terminal 
peptide of CXCL4, namely, CXCL4(47-70), was chemically 
synthesized and purified (51).
interaction of cXcl9(74-93) with soluble 
and cellular gags
To obtain more insight in the contribution of the unique COOH-
terminal region of CXCL9 and in the specificity of CXCL9-derived 
peptides for different GAGs, the affinity of CXCL9(74–93) 
FigUre 1 | The averaged mass spectra of cXcl9(74-93) peptides. The COOH-terminal peptides CXCL9(74-93), NH2-terminally biotinylated CXCL9(74-93), 
and NH2-terminally TAMRA-labeled CXCL9(74-93) were chemically synthesized based on Fmoc-chemistry. The intensity of the detected ions in function of their 
specific mass/charge (m/z) ratio is shown for purified CXCL9(74-93) (a), NH2-terminally biotinylated CXCL9(74-93) (B), and NH2-terminally biotinylated TAMRA-
labeled CXCL9(74-93) (c). In order to calculate the relative molecular mass (Mr) of the proteins corresponding to the indicated ions, Bruker deconvolution software 
was used. The experimentally determined Mr of the peptides are shown as inserts on the upper right of the averaged mass spectra.
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for LMWH, HS, and CS was determined by IFT. The affinity 
(KD value) of CXCL9(74-93) for LMWH, namely, 63 ± 13 nM, 
was comparable to the previously reported KD for LMWH of the 
longer CXCL9(74-103) peptide (61 nM) (42). A biphasic binding 
isotherm was obtained when titrating CXCL9(74-93) with HS, 
indicating more than one binding site for the peptide on this GAG. 
Fitting only the initial high-affinity phase, a KD value of 1  nM 
for HS was obtained. In contrast to the comparable KD values on 
LMWH, CXCL9(74-103) showed about fourfold higher affinity 
for CS (68 ± 4.6 nM) compared to CXCL9(74-93) (296 ± 19 nM).
Because binding of the peptides to cellular GAGs is physiologi-
cally more relevant, binding of biotinylated CXCL9(74-103) and 
CXCL9(74-93) to CHO cells was evaluated by flow cytometric 
analysis. Figure 2A shows dose-dependent binding of the CXCL9 
peptides to CHO cells. Although CXCL9(74-93) and CXCL9(74-
103) bound with comparable affinity to LMWH, CXCL9(74-93) 
displayed lower affinity to cellular GAGs. To ensure that binding 
was GAG-mediated, CHO cells were treated with NaClO3 to 
reduce the sulfation of GAGs. Measuring HS expression with 
a specific anti-HS antibody provides an indication for the total 
GAG expression level, as HS is the most relevant and abundant 
GAG on CHO and endothelial cells (52). Treatment of the CHO 
cells with 100 mM NaClO3 significantly reduced the expression of 
HS with 71.4% as evaluated by flow cytometry (data not shown) 
and consequently the binding of CXCL9(74-93) (Figure 2B).
cXcl9(74-93) competes with cXcl8 for 
Binding to heparin or cellular gags
As recently described, CXCL9(74-103) more potently competes 
with CXCL8 for binding to heparin than CXCL9(74-103) missing 
5 to 12 NH2-terminal residues, stressing the importance of amino 
acids 74–78 for heparin binding (42). To further investigate the 
FigUre 3 | cXcl9(74-93) competes with cXcl8 for binding to 
heparin, heparan sulfate (hs), and cellular glycosaminoglycans 
(gags). Competition between CXCL8 and COOH-terminal CXCL9 or CXCL4 
peptides for binding to immobilized heparin (a) or HS (B) and to Chinese 
hamster ovary (CHO) cells (c) was performed. (a) and (B) CXCL8(1-77) 
(0–300 nM) was added to heparin-coated or HS-coated 96-well plates in the 
presence or absence of the indicated excess of COOH-terminal peptide 
[CXCL9(74-103) (■), CXCL9(74-93) (□), CXCL9(86-103) (Δ), CXCL4(47-70) 
(▴)]. Bound CXCL8 was detected with biotinylated anti-human CXCL8 
antibodies. (c) Binding of NH2-terminally biotinylated CXCL8(1-77) (300 nM) 
to CHO cells in the presence or absence of an excess CXCL9 peptide was 
detected by streptavidin-allophycocyanin and flow cytometry. The mean 
(± SEM) percentage inhibition of binding of CXCL8(1-77) to heparin, HS or 
cellular GAGs is indicated on the y-axis (n ≥ 4). Statistical comparison of the 
different competitors with CXCL9(74–103) was performed using the Mann–
Whitney U-test (*p < 0.05).
FigUre 2 | cXcl9(74-93) interacts with cellular glycosaminoglycans 
(gags). The interaction of the COOH-terminal CXCL9 peptides with Chinese 
hamster ovary (CHO) cells was assessed by flow cytometric analysis.  
(a) CHO cells were treated with dilutions of NH2-terminally biotinylated 
CXCL9(74-103) and CXCL9(74-93), which were detected by streptavidin-
allophycocyanin. (B) To ensure that the binding of CXCL9(74-93) was 
GAG-mediated, CHO cells were treated with sodium chlorate (NaClO3) to 
reduce the sulfation of GAGs. Binding of biotinylated CXCL9(74-93) to cells, 
treated or untreated with NaClO3, was detected by streptavidin-
allophycocyanin. The mean (+SEM) fluorescence intensity of bound 
biotinylated CXCL9 peptides to CHO cells is indicated on the y-axis (n ≥ 4).  
A statistical comparison to evaluate the binding of biotinylated peptides on 
CHO cells [compared to the corresponding concentration of CXCL9(74-103) 
(a) or to the binding to cells not treated with NaClO3 (B)] was performed 
using the Mann–Whitney U-test (*p < 0.05; **p < 0.01).
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role of the COOH-terminal amino acids, the ability of CXCL9 
(74-93) to inhibit binding of chemokines to heparin and HS was 
evaluated. CXCL9(74-93) and CXCL9(74-103) together with a 
COOH-terminal peptide of one of the strongest GAG-binding 
chemokines, namely, CXCL4(47-70), were compared in an ELISA- 
like assay to compete with CXCL8 for heparin binding. As 
evidenced in Figure  3, CXCL9(74-93) competed with CXCL8 
for heparin binding with a similar potency as CXCL9(74-103) 
thereby stressing the importance of amino acids 74–93. For both 
COOH-terminal CXCL9 peptides, a 10-fold molar excess com-
pared to CXCL8 resulted in a 50% reduction of CXCL8 binding 
to heparin (Figure 3A). Recently, it has been shown that CXCL4 
(47-70) binds dose-dependently to GAGs on CHO cells with about 
fivefold lower affinity than CXCL9(74-103) (42). Indeed, also in 
the ELISA-like heparin-binding assay, CXCL4(47-70) was a less 
FigUre 4 | The cOOh-terminal peptides of cXcl9 inhibit cXcl8-induced neutrophil migration to the peritoneal cavity. CXCL8(1-77) was injected into 
the peritoneal cavity of NMRI mice (n ≥ 5) simultaneously with an intraperitoneal (a) or intravenous (B,c) injection of CXCL9(74-103) or CXCL9(74–93). The number 
of neutrophils in the peritoneal cavity, 2 h post injection, were evaluated by differentially counting the leukocyte subtypes on Hemacolor-stained cytospins. The 
neutrophil counts are shown for every individual mouse, and the horizontal lines denote the median percentage. To detect statistically significant differences, the 
Mann–Whitney U-test was carried out (*p < 0.05; **p < 0.01; ***p < 0.005).
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neutrophil migration (data not shown). Also intravenous injection 
of CXCL9(74-103) significantly reduced neutrophil migration 
toward intraperitoneally injected CXCL8 from 148 × 104 neutro-
phils (16.5%) to 81 × 104 neutrophils (10.1%) (Figure 4B). The 
lower doses of CXCL9(74-103) tested were not able to reduce 
the neutrophil migration significantly, although a trend toward a 
lower neutrophil influx was observed upon concomitant intrave-
nous injection of 36 µg CXCL9(74-103). In addition, the inhibi-
tory potential of CXCL9(74–93) was also evaluated in this in vivo 
model. Figure 4C shows that CXCL9(74–93) is an equally potent 
inhibitor of CXCL8 than CXCL9(74-103). Intravenous injection of 
66 µg CXCL9(74-93), an equal molar amount compared to 108 µg 
CXCL9(74–103), significantly reduced the CXCL8-induced neu-
trophil migration to the peritoneum from 192 × 104 neutrophils 
(19%) to 65 × 104 neutrophils (8.25%). Also neutrophil extravasa-
tion to the joint was strongly reduced after intravenous injection 
of 66 µg CXCL9(74–93) from 13.3 × 103 neutrophils (60.5%) to 
0.67 × 103 neutrophils (17.5%) (Figure 5).
Interestingly and in contrast to CXCL9(74-103) (42), 
CXCL9(74-93) could not inhibit MSU crystal-induced neutro-
phil migration to the joint (Figure 5). Therefore, the potency of 
different CXCL9 peptides to compete with chemokines for GAG 
binding was investigated in more detail. Since after injection 
of MSU crystals in the knee cavity the presence of the murine 
CXCR2 ligand CXCL1 is important for neutrophil migration 
(49), competition of CXCL9 peptides with CXCL1 for binding 
to HS was evaluated. Figure 6A demonstrates that CXCL9(74-
93) is a less potent competitor than CXCL9(74-103) for CXCL1 
binding to HS. A threefold molar excess of CXCL9(74-103) 
compared to CXCL1 results in 43% reduction of CXCL1 binding 
to HS, whereas a 10-fold molar excess of CXCL9(74-93) only 
results in 39% reduction. In contrast, CXCL9(86-103) was not 
able to inhibit the interaction between CXCL1 and HS. Since CS 
is generally found in connective tissues, such as cartilage, skin, 
tendons, and ligaments (53, 54), the ability of CXCL9 peptides 
potent competitor of CXCL8 binding than the CXCL9 peptides. 
A more than 100-fold molar excess of CXCL4(47-70) was needed 
to achieve a 50% reduction of CXCL8 binding. On HS-coated 
plates, CXCL9(74-93) and CXCL9(74-103) were equally efficient 
in inhibiting CXCL8 binding (Figure 3B), in contrast to the poorly 
competing CXCL9(86-103). Also on CHO cells, CXCL9(74-93) 
could inhibit the binding of biotinylated CXCL8 to cellular GAGs 
by 31% in the presence of a 30-fold excess of CXCL9(74-93) 
(Figure 3C). A 100-fold excess of CXCL9(74-93) resulted in 50% 
inhibition. On the other hand, a 30-fold excess of CXCL9(74-103) 
could inhibit the binding of CXCL8 by 53%.
cXcl9 Peptides inhibit cXcl8- and MsU 
crystal-induced neutrophil recruitment 
In Vivo
Recently, it was shown that CXCL9(74-103) could inhibit the neu-
trophil chemotactic activity of CXCL8 in vivo when CXCL8 was 
injected into the tibiofemoral articulation of C57BL/6 mice (42). To 
confirm this inhibition of CXCL8-induced neutrophil recruitment 
by CXCL9(74-103) in another body compartment, 1 µg of CXCL8 
was injected intraperitoneally in NMRI mice. Injection of CXCL8 
(1 µg) resulted in significant neutrophil migration to the peritoneal 
cavity, raising the absolute number and percentage of neutrophils 
in the peritoneal cavity to about 142 ×  104 neutrophils (±15%) 
compared to the saline-injected group (21 ×  104 neutrophils). 
Concomitant intraperitoneal injection of 108 µg CXCL9(74-103) 
significantly reduced the potency of CXCL8 to induce neutrophil 
extravasation (Figure 4A). Indeed, upon co-injection of 108 µg 
CXCL9(74-103), the neutrophil accumulation only increased to 
45 × 104 neutrophils (or 6.6%). In contrast, at lower doses tested, 
i.e., 12 and 36 µg, CXCL9(74-103) failed to reduce CXCL8-induced 
neutrophil recruitment. As it could be expected based on the 
heparin-binding assays conducted before (42), 108 µg intraperi-
toneally injected CXCL9(86–103) did not inhibit CXCL8-induced 
FigUre 5 | cXcl9(74-93) inhibits cXcl8-induced but not 
monosodium urate (MsU) crystal-induced neutrophil migration to the 
knee cavity. CXCL8(1-77) (1 µg) or MSU crystals (100 µg) were injected into 
the tibiofemoral articulation of C57BL/6 mice (n ≥ 5). Simultaneously, 66 µg 
of CXCL9(74-93) was injected intravenously and 3 h post injection the 
number of total cells (a) and neutrophils (B) were evaluated by washing the 
cavity and differentially counting the leukocyte subtypes on May-Grunwald-
Giemsa-stained cytospins. The total numbers of leukocytes and neutrophils 
are shown for every individual mouse, and the horizontal lines denote the 
median number of cells. To detect statistically significant differences, the 
Mann–Whitney U-test was carried out (*p < 0.05; **p < 0.01; ***p < 0.005).
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labeled at the NH2-terminus avoiding modification of lysine side 
chains which are known to be important for interaction with 
GAGs. Binding of TAMRA-CXCL9(74-103) to endothelial cells 
was evaluated in the murine cremaster muscle model. Fifty min-
utes after intravenous injection, the peptide was clearly present on 
the vascular surface of the endothelium (Figure 7). In circulation, 
only a fraction of the injected amount (3% or 2  µg/ml) of the 
TAMRA-labeled peptide was detected in the plasma 5 min after 
intravenous injection (assuming a blood volume of 3 ml for the 
mice). Already 1  h after injection, no circulating peptide was 
detected in the plasma (<240 ng/ml). In addition, the effect of 
prior CXCL9(74–103) injection via the jugular vein on chemokine 
superperfusion of the cremaster muscle was analyzed. At differ-
ent time intervals (45, 60, and 90 min) after CXCL8 addition to 
the cremaster muscle superperfusate, neutrophil-endothelial cell 
interactions were registered through intravital microscopy and 
the number of adherent neutrophils was quantified (Figure 8A). 
Intrascrotal injection of 1 µg CXCL8 resulted in an increase in 
adherent neutrophils after 60  min, whereas injection of 3  µg 
CXCL8 already resulted in an increase after 45 min. In both cases 
(1 and 3 µg CXCL8), concomitant intravenous injection of 108 µg 
CXCL9(74-103) reduced the adherence of neutrophils to the 
endothelium significantly (Figure 8B; Video S1 in Supplementary 
Material).
DiscUssiOn
Directional leukocyte migration to specific primary, secondary, 
or tertiary lymphoid organs is important for normal functioning 
of our immune system. In addition, it is a crucial phenomenon 
to clear pathogens from sites of infection, to kill malignant cells, 
and to restore tissue damage. The interplay between adhesion 
molecules such as selectins and integrins, chemoattractants, and 
their receptors guides this process (17, 18, 55, 56). In order to 
prevent wash-out of chemokines from the surface of endothe-
lial cells, chemokines can bind to negatively charged GAGs 
(18, 57, 58). These GAGs are linear polysaccharides which 
consist of repeating disaccharide subunits and dependent on the 
subunit they will be classified into different classes, e.g., heparin, 
HS, and CS (59). Heparin consists of repeating glucuronic acid 
and N-acetyl glucosamine residues and is highly sulfated with 
80–90% N-sulfated glucosamine units. In contrast, HS consists 
of iduronic acid and is less sulfated with only 30–60% of the 
glucosamine units being N-sulfated. An extra level of complex-
ity is the high degree of variations in GAG (e.g., HS) structures 
in different organs (60). It has been shown that chemokines 
localize within capillary venules in a GAG-dependent way to 
create a chemotactic gradient and destruction of these gradi-
ents results in abrogated directional migration of leukocytes 
(12, 13). Through interaction with GAGs chemokines can also 
form gradients in tissues along which leukocytes can migrate 
to the site of inflammation (13, 14). This interaction occurs 
between GAG-binding motifs in the chemokine and the sulfated 
domains in the GAG.
Three human chemokines, i.e., CXCL9, CXCL12γ, and CCL21, 
possess an elongated COOH-terminal tail which is highly posi-
tively charged. Linking the COOH-terminal tail of CCL21 to the 
to compete with CXCL1 for binding to CS was evaluated also. 
Again, three times more CXCL9(74-93) than CXCL9(74-103) 
was needed to achieve the same reduction of CXCL1 binding 
to CS (Figure  6B). In addition, the maximum inhibition of 
CXCL1 binding achieved by competition with CXCL9(74-103) 
(72% for HS and 63% for CS) was higher than the maximum 
inhibition achieved by competition with CXCL9(74–93) 
(52% for HS and CS).
cXcl9(74-103) Binds to endothelial cells 
and Prevents adhesion of Peripheral 
Mononuclear cells in the Murine 
cremaster Muscle Model
To evaluate the binding of CXCL9(74-103) to the endothelium 
in vivo, the peptide was site-specifically fluorescently (TAMRA-)
FigUre 6 | cXcl9(74-93) is a less potent competitor for cXcl1 binding to glycosaminoglycans (gags). Competition between CXCL1 and COOH-
terminal CXCL9 peptides for binding to immobilized heparan sulfate (HS) (a) and chondroitin sulfate (CS) (B) was performed. Dilutions of CXCL1 were added to 
GAGs in 96-well plates in the presence or absence of the indicated excess of COOH-terminal peptide [CXCL9(74-103) (■), CXCL9(74-93) (□), CXCL9(86-103) (Δ)]. 
Bound CXCL1 was detected with biotinylated polyclonal goat anti-mouse CXCL1 antibodies. The mean (± SEM) percentage inhibition of CXCL1 binding to GAGs is 
indicated on the y-axis (n ≥ 3). Statistical comparison of the different competitors with CXCL9(74–103) was performed using the Mann–Whitney U-test.
FigUre 7 | Binding of TaMra-labeled cXcl9(74-103) to the vascular 
surface of the endothelium. Binding of the TAMRA-labeled CXCL9(74-
103) to endothelial cells was evaluated in the murine cremaster muscle 
model. Fluorescent peptide (100 µg) was injected intravenously and binding 
to the vascular surface of the endothelium was visualized by confocal in vivo 
imaging 50 min after injection.
FigUre 8 | cXcl9(74-103) inhibits adhesion of neutrophils in the 
murine cremaster muscle model. (a) Neutrophil adhesion to the 
endothelium in response to an intrascrotal injection of 1 or 3 µg CXCL8 in the 
presence or absence of 108 µg intravenously injected CXCL9(74-103) was 
quantified at different time points (45, 60, and 90 min). (B) The cremaster of 
mice was superfused with 1 (i and iii) or 3 µg (ii and iv) of CXCL8 and 
endothelium was stained with anti-PECAM-1/CD31 antibody coupled to 
Alexa 647. The adhering neutrophils were visualized with an anti-Ly6G 
antibody conjugated to PE and quantified at 60 min post CXCL8 injection. In 
addition, mice were injected intravenously with either saline (i and ii) or 
CXCL9(74-103) (iii and iv) 5 min prior to the intrascrotal injection of CXCL8.
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related CCR7 ligand CCL19 enhanced its affinity for heparin 
(61). Cooperativity between CCL21 and other chemokines was 
shown to depend on this GAG-binding COOH-terminal domain 
(62) and the COOH-terminal tail of CCL21 reduced its in vitro 
chemotactic potency in a 3D dendritic cell chemotaxis assay, 
but enhanced its efficiency to activate ERK1/2 signaling and 
β-arrestin recruitment (63). In addition, full-length CCL21 was 
shown to induce integrin-dependent dendritic cell spreading, 
polarization and haptotactic movement, whereas CCL21 missing 
the positively charged C-terminus induced non-adhesive and 
integrin-independent directional migration (64). Also CXCL12γ 
appeared to be a weaker chemoattractant than CXCL12α in assays 
studying migration through uncoated chemotaxis membranes 
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(65). However, CXCL12γ attracted T cells through an endothelial 
layer. The highly charged COOH-terminal domain of CCL12γ 
was shown to interact with sulfotyrosines on CXCR4 thereby 
enhancing its affinity for the receptor but reducing the signal. 
HS was able to inhibit binding of CXCL12γ to sulfotyrosines 
of CXCR4 and converted CXCL12γ into a functional CXCR4 
ligand. Recently, we identified natural forms of CXCL9 missing 
the COOH-terminal domain that retained CXCR3 signaling 
potency (42).
In several inflammatory diseases, an enhanced expression 
of chemokines leads to the pathological and continuous accu-
mulation of activated leukocytes in tissues and consequently 
tissue damage. Thus, a reduction of chemokine activity at sites 
of excessive inflammation is needed. Although a lot of efforts 
were invested in the development of small molecule chemokine 
receptor antagonists, since the discovery of chemokine receptors 
as members of the GPCR family about two decades ago, success 
stories are limited to a few drugs that entered the market (66). 
Recently, inhibition of chemokine–GAG interaction has been 
explored as a complementary alternative for chemokine receptor 
antagonists. Both modified chemokines with enhanced GAG 
interaction and reduced activity on GPCRs, and aptamers that 
interfere with chemokine–GAG binding have entered clinical 
development (40, 41). The COOH-terminal CXCL9 domain 
CXCL9(74-103) potently bound GAGs, competed for GAG 
binding with several chemokines and was able to inhibit CXCL8- 
and MSU crystal-induced leukocyte migration to joints (42). In 
addition, the CXCL9(74-103) and COOH-terminal CXCL12γ 
peptides were able to inhibit viral infection of cells with dengue 
virus, herpes simplex virus-1 and respiratory syncytial virus due 
to competition with the viruses for GAG binding (43).
In this study, we investigated in detail the role of the COOH-
terminal part of CXCL9 for its affinity and specificity toward 
different GAGs. IFT showed that both COOH-terminal pep-
tides, i.e., CXCL9(74-103) and CXCL9(74-93), show high and 
comparable affinity for LMWH and HS. CXCL9(74-93), which 
contains the two NH2-terminal and crucial GAG-binding motifs 
of CXCL9(74-103), competed equally efficient with CXCL8 for 
binding to immobilized heparin and HS. However, the affinity 
for CS and the binding of CXCL9(74-93) to cellular GAGs on 
CHO cells is lower compared to CXCL9(74-103). This suggests 
that on the surface of CHO cells not only HS, but a mixture of 
FigUre 9 | The anti-inflammatory activity of cXcl9(74-93) in murine models of neutrophil migration. In the peritoneum, both CXCL9(74-93) and 
CXCL9(74-103) inhibit CXCL8-induced neutrophil migration. Because of the high affinity of both peptides for heparan sulfate (HS), it can be suggested that HS is 
important for the creation of a CXCL8-dependent chemotactic gradient in the peritoneum. In that way, the CXCL9 peptides compete with CXCL8 and inhibit 
neutrophil extravasation. Although chondroitin sulfate (CS) is most abundant in the articular cavity and the affinity of the peptides for CS is different, both peptides 
are able to inhibit CXCL8-induced neutrophil migration to the knee cavity. In the gout model, the lower efficiency of CXCL9(74-93) to inhibit CS binding of the 
induced murine chemokines does not prevent neutrophil migration.
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different GAGs are expressed and are important for the binding 
of the COOH-terminal peptides. Analogously, CXCL9(74-93) is 
not able to compete with CXCL8 for binding to cellular GAGs 
to the same degree as CXCL9(74-103). Thus, the removal of 
the 10 COOH-terminal amino acids of CXCL9(74-103) results 
in a certain specificity toward LMWH and HS (and loss of CS 
binding). Previously, it has been described that the motifs BBXB 
and BBBXXB in proteins, in which B represents a basic and X 
represents any non-basic amino acid, are important for GAG 
binding (67). Both CXCL9(74-103) and CXCL9(74-93) contain 
the same GAG-binding motifs (Lys75-Lys78 and Lys85-Lys90). 
However, CXCL9(74-93) lacks the remaining COOH-terminal 
amino acids. This modification influenced the interaction with 
GAGs, thereby indicating a certain degree of specificity of the 
peptides for different GAGs. It can be suggested that the change 
of GAG affinity and specificity between both peptides is due to 
the presence of a “reversed” GAG-binding domain (BXBB instead 
of BBXB) in the COOH-terminal region of CXCL9(74-103) 
between Arg-98 and Lys-101.
In view of the variation in GAG structures between different 
organs, we investigated the importance of chemokine-GAG 
interactions in the inflammatory response upon injection of 
CXCL8 or MSU crystals in different tissues, i.e., the peritoneal 
and/or knee cavity and the cremaster muscle. Although mice 
lack the gene for CXCL8, a strong neutrophilic inflammation 
can be induced when CXCL8 is administered in mice (42, 68). 
In addition, the capacity of CXCL9(74-93) to inhibit MSU 
crystal-induced neutrophil migration was assessed. Both upon 
intraperitoneal or intra-articular injection of CXCL8, con-
comitant injection of CXCL9(74-103) or CXCL9(74–93) was 
able to inhibit neutrophil-dependent inflammation. Our results 
also show that CXCL9(74-93), when given intravenously in 
equimolar concentrations, could inhibit CXCL8 activity in vivo 
with similar potency as CXCL9(74-103). On the contrary, 
CXCL9(74-93) was not able to inhibit neutrophil extravasation 
in the more complex and less chemoattractant-specific MSU 
crystal-induced gout model. This difference in anti-inflammatory 
activity can be explained in several ways (Figure  9). First, it 
is known that in the articular cavity CS is an abundant GAG, 
comprising 60–90% of the GAG molecules (69, 70). Keeping in 
mind that CXCL9(74-93) binds with lower affinity to CS, it can 
be suggested that this peptide cannot compete with chemokines 
for binding to CS in the same way as CXCL9(74-103). Indeed, 
CXCL9(74-93) is a less potent competitor for CXCL1 binding to 
HS and CS (Figure 6), a previously reported major neutrophil 
chemoattractant in this gout model (49). Second, it is known 
that chemokines bind with different affinity and/or specific-
ity to different GAGs (71, 72). In the gout model, the induced 
murine chemokines (CXCL1 and CXCL2 (49)) probably bind 
with different affinity or specificity to different GAGs in the 
murine knee cavity than human CXCL8. This would explain why 
a peptide with lower affinity for those GAGs cannot compete 
with the induced murine chemokines. In conclusion, both the 
affinity and the specificity of the peptides and the chemokines 
for different GAGs will determine whether competition can 
occur. Finally, we investigated whether the more potent CXCL9 
(74-103) peptide could inhibit the activity of CXCL8 in the murine 
cremaster muscle model. In this model, CXCL8 was injected 
intrascrotally into the cremaster muscle to induce adhesion of 
neutrophils to the endothelium. Intravital microscopy of the 
muscle clearly shows that the fluorescent CXCL9 peptide binds 
to the endothelium. In this way, CXCL8 was not able to bind to 
GAGs and direct evidence was provided for lower adhesion of 
neutrophils to the endothelium.
Thus, overall we show that CXCL9(74-103) indeed inhibits 
neutrophil migration in  vivo through interference with GAG 
interactions in three animal models and that shortening this 
CXCL9 from the COOH-terminus increases its specificity for 
particular GAGs. Obtaining detailed knowledge on the specificity 
of these GAG-binding peptides is important for the development 
of lead molecules for the generation of therapeutics competing 
with active chemokines for GAG binding to avoid potential side 
effects.
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